KWM
ESPR

Kingsview Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Kingsview Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$67K – 1058
2024
Q1 		$67K Sell
25,000
-6,500
-21% -$15.8K ﹤0.01% 1001
2023
Q4 		$94.2K Buy
+31,500
New +$40.9K ﹤0.01% 930

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingsview Wealth Management's ESPR Position: Q2 2024 in Review

Kingsview Wealth Management sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 25,000 shares — an estimated $67K sold.

Kingsview Wealth Management first reported a position in ESPR in Q4 2023 and held it in 2 quarters. The position peaked at $94.2K in Q4 2023. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Kingsview Wealth Management reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Kingsview Wealth Management sold 25,000 Esperion Therapeutics shares in Q2 2024, an estimated $67K.
  • Kingsview Wealth Management first reported a position in Esperion Therapeutics in Q4 2023 and held it in 2 quarters.
  • Kingsview Wealth Management's Esperion Therapeutics position peaked at $94.2K in Q4 2023.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Kingsview Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.